Indaptus Therapeutics, Inc. has 11 Schedule 13D or 13G filings on record since 2025-12-30. 7 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lazar David E. | 47.93% | 2,064,000 | SCHEDULE 13D/A, 2026-03-24 | 2026-03-23 |
| Yao Yun | 31.51% | 41,991,000 | SCHEDULE 13D/A, 2026-06-26 | 2026-06-24 |
| Sino Lion Ventures Ltd | 29.19% | 38,895,000 | SCHEDULE 13D/A, 2026-06-26 | 2026-06-24 |
| Jeffery A. Meckler | 12.7% | 273,103 | SCHEDULE 13D/A, 2025-12-30 | 2025-12-22 |
| Yang Ting | 8.44% | 11,250,000 | SCHEDULE 13D/A, 2026-06-26 | 2026-06-24 |
| Dai Junyi | 8.44% | 11,250,000 | SCHEDULE 13D/A, 2026-06-26 | 2026-06-24 |
| Newman Michael James | 5.4% | 115,552 | SCHEDULE 13D/A, 2025-12-30 | 2025-12-22 |
| YA II PN, Ltd. | 0% | 0 | SCHEDULE 13G/A, 2026-04-06 | 2025-12-31 |
Purpose of Transaction (Item 4)
Lazar David E.
Item 4 is hereby amended to add the following: Following the completion of the transactions set forth in the March 2026 SPA (as defined below), the Reporting Person has resigned as co-Chief Executive Officer of the Issuer. The Reporting Person will remain a member of the Issuer's Board of Directors.Item 4 of the SCHEDULE 13D/A filed 2026-03-24
Yao Yun
The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 2 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the increase in the number of shares of Common Stock issued and outstanding upon the closing of the Issuer's private placement on June 17, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith.Item 4 of the SCHEDULE 13D/A filed 2026-06-26
Yang Ting
The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 2 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the increase in the number of shares of Common Stock issued and outstanding upon the closing of the Issuer's private placement on June 17, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith.Item 4 of the SCHEDULE 13D/A filed 2026-06-26
Dai Junyi
The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 2 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the increase in the number of shares of Common Stock issued and outstanding upon the closing of the Issuer's private placement on June 17, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith.Item 4 of the SCHEDULE 13D/A filed 2026-06-26
Sino Lion Ventures Ltd
The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 2 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Persons, resulting solely from the increase in the number of shares of Common Stock issued and outstanding upon the closing of the Issuer's private placement on June 17, 2026. The Reporting Persons did not acquire or dispose of any shares of Common Stock in connection therewith.Item 4 of the SCHEDULE 13D/A filed 2026-06-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-30 | Newman Michael James | 5.4% | SCHEDULE 13D/A |
| 2025-12-30 | Jeffery A. Meckler | 12.7% | SCHEDULE 13D/A |
| 2026-03-02 | Lazar David E. | 98% | SCHEDULE 13D |
| 2026-03-24 | Lazar David E. | 47.93% | SCHEDULE 13D/A |
| 2026-03-30 | Yao Yun | 37.8% | SCHEDULE 13D |
| 2026-04-06 | YA II PN, Ltd. | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Yao Yun | 37.1% | SCHEDULE 13D/A |
| 2026-06-26 | Yao Yun | 31.51% | SCHEDULE 13D/A |
| 2026-06-26 | Yang Ting | 8.44% | SCHEDULE 13D/A |
| 2026-06-26 | Dai Junyi | 8.44% | SCHEDULE 13D/A |
| 2026-06-26 | Sino Lion Ventures Ltd | 29.19% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Indaptus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.